Literature DB >> 19884751

Amikacin-induced type 5 Bartter-like syndrome with severe hypocalcemia.

A Chrispal1, H Boorugu, A T Prabhakar, V Moses.   

Abstract

Aminoglycoside-induced renal toxicity is well known and may manifest with nonoliguric renal failure or renal tubular dysfunction. Aminoglycoside-induced renal tubular dysfunction could result in diffuse damage or manifest as a Fanconi-like syndrome, Bartter-like syndrome, or distal renal tubular acidosis. We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria. This constellation of biochemical abnormalities mimic Type 5 Bartter's syndrome, where there is activating mutation of the calcium sensing receptor in the thick ascending loop of Henle and the distal tubule. In this case this activation of the calcium sensing receptor was triggered by amikacin. This phenomenon has been described with gentamicin though never with amikacin. Recovery of the tubular dysfunction took 15 days following cessation of the offending drug, Amikacin.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19884751     DOI: 10.4103/0022-3859.57407

Source DB:  PubMed          Journal:  J Postgrad Med        ISSN: 0022-3859            Impact factor:   1.476


  15 in total

Review 1.  Molecular pathophysiology of Bartter's and Gitelman's syndromes.

Authors:  Efstathios Koulouridis; Ioannis Koulouridis
Journal:  World J Pediatr       Date:  2015-03-09       Impact factor: 2.764

2.  Transient Bartter-like syndrome in a child with extensively drug-resistant tuberculosis: Answers.

Authors:  Vishrutha Sujith Poojari; Ira Shah; Naman S Shetty; Akanksha Jaiswal
Journal:  Pediatr Nephrol       Date:  2020-11-05       Impact factor: 3.714

Review 3.  Bartter- and Gitelman-like syndromes: salt-losing tubulopathies with loop or DCT defects.

Authors:  Hannsjörg W Seyberth; Karl P Schlingmann
Journal:  Pediatr Nephrol       Date:  2011-04-19       Impact factor: 3.714

4.  Primary molecular disorders and secondary biological adaptations in bartter syndrome.

Authors:  Georges Deschênes; Marc Fila
Journal:  Int J Nephrol       Date:  2011-09-20

5.  Review on the Antimicrobial Resistance of Pathogens from Tracheal and Endotracheal Aspirates of Patients with Clinical Manifestations of Pneumonia in Bacolod City in 2013.

Authors:  Alain C Juayang; Dominador G Maestral; Gemma B de Los Reyes; Michael Angelo D Acosido; Christine T Gallega
Journal:  Int J Bacteriol       Date:  2015-02-03

6.  Bartter syndrome-like phenotype in a patient with diabetes: a case report.

Authors:  Chamara Dalugama; Manoji Pathirage; S A M Kularatne
Journal:  J Med Case Rep       Date:  2018-08-17

Review 7.  Hypomagnesemia: a clinical perspective.

Authors:  Phuong-Chi T Pham; Phuong-Anh T Pham; Son V Pham; Phuong-Truc T Pham; Phuong-Mai T Pham; Phuong-Thu T Pham
Journal:  Int J Nephrol Renovasc Dis       Date:  2014-06-09

8.  Hypercalcemia-Induced Hypokalemic Metabolic Alkalosis in a Multiple Myeloma Patient: The Risk of Furosemide Use.

Authors:  Ira W Reiser; Slamat Ali; Vladimir Gotlieb; Samuel Spitalewitz
Journal:  Case Rep Oncol       Date:  2015-09-18

9.  Acquired Bartter syndrome following gentamicin therapy.

Authors:  J Singh; M L Patel; K K Gupta; S Pandey; A Dinkar
Journal:  Indian J Nephrol       Date:  2016 Nov-Dec

Review 10.  An overview of diagnosis and management of drug-induced hypomagnesemia.

Authors:  George Liamis; Ewout J Hoorn; Matilda Florentin; Haralampos Milionis
Journal:  Pharmacol Res Perspect       Date:  2021-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.